KYMR Q1 2022 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-48.6% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$37M-383.8% margin

Net Income

-$37M-381.3% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

-37.0%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$41M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$563M

Total Liabilities

$134M

Stockholders' Equity

$429M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$19M	-48.6%
Gross Profit	$10M	$19M	-48.6%
Operating Income	-$37M	-$13M	-180.5%
Net Income	-$37M	-$13M	-180.6%